Clinical
RSSArticles
-
Prophylactic PCI for Vulnerable Plaques
In this proof-of-concept trial, treatment of non-flow limiting vulnerable plaque by PCI with bioabsorbable stents resulted in no significant difference in lesion-related events compared with optimal medical therapy.
-
Does MRSA Nares Colonization Predict Non-Respiratory MRSA Infections?
Nares screening for methicillin-resistant Staphylococcus aureus (MRSA) carried a high negative predictive value to rule out MRSA infections at various sites.
-
Air Pollution and Cognitive Decline
In this large prospective cohort study of subjects in Manhattan, researchers demonstrated an association between exposure to air pollution and decline in cognitive function over time in one cohort, but not the other.
-
Improve Diet to Put Out the GERD Fire
The authors estimated nearly 40% of gastroesophageal reflux disease symptoms that occur at least weekly can be prevented through a modification of lifestyle factors.
-
Researchers Raise Awareness About Antibiotic Resistance in Racial, Ethnic Minorities
Investigators list factors that indicate this might be a hidden problem.
-
American Heart Association Acknowledges Psychological, Heart Health Connections
The authors of a scientific statement call for psychological health screening and treatment to be a part of caring for patients at risk for cardiovascular disease.
-
Biden Administration Takes First Steps Against COVID-19
The new president signed a series of executive actions to accelerate nation’s pandemic response.
-
Clinical and Genetic Characterizations to Diagnose Sarcoglycanopathies
Sarcoglycanopathies, caused by various genetic mutations, may cause limb-girdle forms of muscular dystrophy early in life. Although there are no specific treatments for these disorders at this time, the clinical and genetic characterizations will assist in more precise diagnosis that will be critical to develop new molecular-based therapies.
-
Prednisone vs. Placebo in Short-Term Prevention of Episodic Cluster Headaches
Prednisone, given at 100 mg for five days and then tapering by 20 mg every three days, is a safe and effective short-term prevention for episodic cluster headaches while waiting for longer-acting preventive agents to be initiated.
-
Cognitive Benefit of Rivastigmine in Parkinson’s Disease Dementia with Orthostatic Hypotension
Individuals with Parkinson’s disease dementia and orthostatic hypotension (OH) have more robust cognitive improvement from rivastigmine compared to those without OH. This greater response possibly is mediated by the anti-OH effect of rivastigmine.